Lowest Price Guaranteed
Pages
382
Last Updated
September 2026
View Count
12936
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cell Therapies
3.2.1. Classification of Stem Cell Therapies by Type of Cells
3.2.1.1. Embryonic Stem Cells
3.2.1.2. Adult Stem Cells
3.2.1.3. Induced Pluripotent Stem Cells
3.2.1.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
3.2.2. Applications of Stem Cell Therapies
3.3. Overview of Cardiovascular Disorders
3.3.1. Key Indications being Investigated for Treatment with Stem Cells
3.4. Overview of Metabolic Disorders
3.4.1. Key Indications being Investigated for Treatment with Stem Cells
3.5. Administration of Stem Cell Therapies
3.6. Challenges Associated with Developing Stem Cell Therapies
3.7. Future Perspectives
3.7.1. Cardiovascular Disorders
3.7.2. Metabolic Disorders
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
4.2.1. Analysis by Target Therapeutic Area
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Source of Stem Cells
4.2.4. Analysis by Type of Stem Cells
4.2.5. Analysis by Stem Cell Lineage
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Target Indication
4.2.7.1. Cardiovascular Disorders
4.2.7.2. Metabolic Disorders
4.2.8. Key Developers
4.2.9. Heptagon Representation: Analysis by Target Indication and Phase of Development of Stem Cell Therapies
4.2.10. Grid Analysis: Target Indications, Phase of Development and Source of Stem Cells
4.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Landscape
4.3.1. Distribution by Focus Area
4.3.2. Distribution by Year of Establishment
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Geographical Location
4.3.5. Distribution by Location of Stem Cell Manufacturing Facilities of Developer
4.3.6. Mapping Regional Activity
4.3.7. Logo Landscape: Analysis by Size and Target Therapeutic Area
4.4. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Additional Information
4.4.1. Information on Dosage
4.4.2. Information on Designations Awarded
4.4.3. Other Therapeutic Indications under Evaluation
4.5. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Contributions from Academia
4.6. Stem Cell Therapies for Stroke
5. UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs in Cardiovascular and Metabolic Disorders Market
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights: Cardiovascular Disorders
5.2.1.3. Key Insights: Metabolic Disorders
5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.2.2.1. Unmet Needs by Type of Indication
5.2.2.2.2. Unmet Needs by Stem Cell Lineage
5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights: Cardiovascular Disorders
5.2.3.3. Key Insights: Metabolic Disorders
5.2.4. Expert Opinions
5.2.4.1. Cardiovascular Disorders
5.2.4.1.1. Charles E Murry, Institute for Stem Cell and Regenerative Medicine
5.2.4.1.2. Stuart Conolly, McMaster University
5.2.4.1.3. Akshay Desai, Harvard Medical School; Sheryl Chow, Western University of Health Sciences College of Pharmacy; Scott Solomon, Harvard Medical School; Orly Vardeny, William S. Middleton Memorial VA Hospital
5.2.4.1.4. Naser M Ammash, Mayo Clinic and Joseph A Dearani, Mayo Clinic
5.2.4.1.5. Julie Anne Mitchell, Heart Foundation
5.2.4.1.6. Andre Terzic, Mayo Clinic and Atta Behfar, Mayo Clinic
5.2.4.2. Metabolic Disorders
5.2.4.2.1. Heather A Lau, Lysosomal Storage Disease Program, NYU Langone
5.2.4.2.2. Larry Hirsch, BD Diabetes Care
5.2.4.2.3. Michael Hirst, International Diabetes Federation; David Strain, University of Exeter Medical School in the UK; Xavier Cos, Sant Marti de Provençals Primary Care Centres
5.2.5. Summary of Key Unmet Needs in Cardiovascular and Metabolic Disorders
6. KEY THERAPEUTIC AREAS FOR STEM CELL THERAPIES
6.1. Chapter Overview
6.2. Cardiovascular Disorders
6.2.1. Heart Failure
6.2.1.1. Overview
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Pharmacological Interventions
6.2.1.3.2. Therapeutic Devices
6.2.1.3.3. Surgery
6.2.1.4. Stem Cell Therapies for Heart Failure
6.2.2. Myocardial Infarction
6.2.2.1. Overview
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Landscape
6.2.2.3.1. Pharmacological Interventions
6.2.2.3.2. Surgery
6.2.2.4. Stem Cell Therapies for Myocardial Infarction
6.2.3. Critical Limb Ischemia
6.2.3.1. Overview
6.2.3.2. Epidemiology
6.2.3.3. Current Treatment Landscape
6.2.3.3.1. Pharmacological Interventions
6.2.3.3.2. Endovascular Treatments
6.2.3.3.3. Surgery
6.2.3.4. Stem Cell Therapies for Critical Limb Ischemia
6.3. Metabolic Disorders
6.3.1. Diabetes
6.3.1.1. Overview
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Landscape
6.3.1.3.1. Insulin Therapies
6.3.1.3.2. Non-Insulin Therapies
6.3.1.3.3. Surgery
6.3.1.4. Stem Cell Therapies for Diabetes
7. COMPANY COMPETITIVENESS ANALYSIS
7.1 Chapter Overview
7.2 Methodology
7.3 Assumptions and Key Parameters
7.4 Competitiveness Analysis
7.4.1. Companies Developing Stem Cell Therapies for Cardiovascular Disorders
7.4.2. Companies Developing Stem Cell Therapies for Metabolic Disorders
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnerships
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Therapeutic Area
8.3.4. Regional Analysis
8.3.4.1. Local and International Agreements
8.3.4.2. Intercontinental and Intracontinental Agreements
8.3.5. Most Active Players: Analysis by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Type of Stem Cells
9.3.6. Most Active Players
9.4. Concluding Remarks
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Publications
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Key Journals
10.3.3. Analysis by Type of Study
10.3.4. Analysis by Type of Disorder
10.3.4.1. Cardiovascular Disorders
10.3.4.2. Metabolic Disorders
10.3.5. Analysis by Stem Cell Lineage
10.3.6. Analysis by Stem Cell Lineage and Focused Indication
10.3.7. Emerging Areas of Focus
11. STEM CELL THERAPIES FOR CARDIOVASCULAR DISORDERS: THERAPY PROFILES
11.1. Chapter Overview
11.2. Stempeucel (Stempeutics Research)
11.2.1. Therapy Overview
11.2.2. History of Development
11.2.3. Technology Overview
11.2.4. Current Development Status
11.2.5. Key Clinical Trial Results
11.2.6. Dosing, Price and Manufacturing
11.3. Autologous Bone Marrow Concentrate (aBMC) (Cesca Therapeutics)
11.3.1. Therapy Overview
11.3.2. History of Development
11.3.3. Technology Overview
11.3.4. Current Development Status
11.3.5. Key Clinical Trial Results
11.4. BCDA-01 (BioCardia)
11.4.1. Therapy Overview
11.4.2. History of Development
11.4.3. Technology Overview
11.4.4. Current Development Status
11.4.5. Key Clinical Trial Results
11.5. BCDA-02 (BioCardia)
11.5.1. Therapy Overview
11.5.2. History of Development
11.5.3. Technology Overview
11.5.4. Current Development Status
11.5.5. Key Clinical Trial Results
11.6. CLBS14-NORDA (Caladrius Biosciences)
11.6.1. Therapy Overview
11.6.2. History of Development
11.6.3. Technology Overview
11.6.4. Current Development Status
11.6.5. Key Clinical Trial Results
11.7. MPC-150-IM (Mesoblast)
11.7.1. Therapy Overview
11.7.2. History of Development
11.7.3. Technology Overview
11.7.4. Current Development Status
11.7.5. Key Clinical Trial Results
11.8. PLX-PAD (Pluristem Therapeutics)
11.8.1. Therapy Overview
11.8.2. History of Development
11.8.3. Technology Overview
11.8.4. Current Development Status
11.8.5. Key Clinical Trial Results
12. STEM CELL THERAPIES FOR METABOLIC DISORDERS: THERAPY PROFILES
12.1. Chapter Overview
12.2. Strimvelis (Orchard Therapeutics)
12.2.1. Therapy Overview
12.2.2. History of Development
12.2.3. Technology Overview
12.2.4. Current Development Status
12.2.5. Key Clinical Trial Results
12.2.6. Dosing, Price and Manufacturing
12.3. OTL-200 (Orchard Therapeutics)
12.3.1. Therapy Overview
12.3.2. History of Development
12.3.3. Technology Overview
12.3.4. Current Development Status
12.3.5. Key Clinical Trial Results
12.4. Stem Cell Therapy (Global Cell Med)
12.4.1. Therapy Overview
12.4.2. History of Development
12.4.3. Technology Overview
12.4.4. Current Development Status
12.4.5. Key Clinical Trial Results
12.5. LMSCs (Longeveron)
12.5.1. Therapy Overview
12.5.2. History of Development
12.5.3. Current Development Status
12.6. Stem Cell Educator Therapy (Tianhe Stem Cell Biotechnologies)
12.6.1. Therapy Overview
12.6.2. History of Development
12.6.3. Technology Overview
12.6.4. Current Development Status
12.6.5. Key Clinical Trial Results
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders, Till 2030
13.3.1. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Till 2030
13.3.2. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Till 2030
13.3.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Till 2030
13.3.4. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Till 2030
13.4. Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Till 2030
13.4.1. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Till 2030
13.4.2. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Till 2030
13.4.3. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Till 2030
13.4.4. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Till 2030
13.4.5. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Till 2030
13.4.6. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Till 2030
13.4.7. Stem Cell Therapies Market for Cardiovascular Disorders: Myocardial Infarction, Till 2030
13.4.7.1. Cellgram®-AMI (Pharmicell)
13.4.7.1.1 Target Patient Population
13.4.7.1.2. Sales Forecast
13.4.7.1.3. Sales Forecast by Geography
13.4.7.2. Cardiocell® (Cytopeutics)
13.4.7.2.1. Target Patient Population
13.4.7.2.2. Sales Forecast
13.4.7.2.3. Sales Forecast by Geography
13.4.8. Stem Cell Therapies Market for Cardiovascular Disorders: Heart Failure, Till 2030
13.4.8.1. HeartSheet® (Terumo BCT)
13.4.8.1.1. Target Patient Population
13.4.8.1.2. Sales Forecast
13.4.8.1.3. Sales Forecast by Geography
13.4.8.2. MPC-150-IM (Mesoblast)
13.4.8.2.1. Target Patient Population
13.4.8.2.2. Sales Forecast
13.4.8.2.3. Sales Forecast by Geography
13.4.8.3. BCDA-01 (BioCardia)
13.4.8.3.1. Target Patient Population
13.4.8.3.2. Sales Forecast
13.4.8.3.3. Sales Forecast by Geography
13.4.8.4. Cardiocell® (Cytopeutics)
13.4.8.4.1. Target Patient Population
13.4.8.4.2. Sales Forecast
13.4.8.4.3. Sales Forecast by Geography
13.4.9. Stem Cell Therapies Market for Cardiovascular Disorders: Critical Limb Ischemia, Till 2030
13.4.9.1. Stempeucel® (Stempeutics Research)
13.4.9.1.1. Target Patient Population
13.4.9.1.2. Sales Forecast
13.4.9.1.3. Sales Forecast by Geography
13.4.9.2. PLX-PAD (Pluristem Therapeutics)
13.4.9.2.1. Target Patient Population
13.4.9.2.2. Sales Forecast
13.4.9.2.3. Sales Forecast by Geography
13.4.9.3. Cardiocell® (Cytopeutics)
13.4.9.3.1. Target Patient Population
13.4.9.3.2. Sales Forecast
13.4.9.3.3. Sales Forecast by Geography
13.4.10. Stem Cell Therapies Market for Cardiovascular Disorders: Other Indications, Till 2030
13.4.10.1. CLBS14-NORDA (Caladrius Biosciences )
13.4.10.1.1. Target Patient Population
13.4.10.1.2. Sales Forecast
13.4.10.1.3. Sales Forecast by Geography
13.4.10.2. BCDA-02 (BioCardia)
13.4.10.2.1. Target Patient Population
13.4.10.2.2. Sales Forecast
13.4.10.2.3. Sales Forecast by Geography
13.5. Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Till 2030
13.5.1. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Till 2030
13.5.2. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Till 2030
13.5.3. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Till 2030
13.5.4. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Till 2030
13.5.5. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cell Lineage, Till 2030
13.5.6. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Till 2030
13.5.7. Stem Cell Therapies Market for Metabolic Disorders: ADA-SCID, Till 2030
13.5.7.1. Strimvelis® (Orchard Therapeutics)
13.5.7.1.1. Target Patient Population
13.5.7.1.2. Sales Forecast
13.5.7.1.3. Sales Forecast by Geography
13.5.8. Stem Cell Therapies Market for Metabolic Disorders: Metachromatic Leukodystrophy, Till 2030
13.5.8.1. OTL-200 (Orchard Therapeutics)
13.5.8.1.1. Target Patient Population
13.5.8.1.2. Sales Forecast
13.5.8.1.3. Sales Forecast by Geography
13.5.9. Stem Cell Therapies Market for Metabolic Disorders: Diabetes, Till 2030
13.5.9.1. Unnamed Stem Cell Therapy by Global Cell Med
13.5.9.1.1. Target Patient Population
13.5.9.1.2. Sales Forecast
13.5.9.1.3. Sales Forecast by Geography
14. CONCLUSION
14.1. The Treatment Landscape of Cardiovascular and Metabolic Disorders is Characterized by Several Unmet Needs; Stem Cell Therapies have Demonstrated the Potential to Offer Viable and Lasting Therapeutic Effect
14.2. The Market Features a Promising Pipeline with Several Mid and Late Stage Product Therapies, which are Mostly based on Adult Stem Cells
14.3. The Fragmented Developer Landscape Includes Small, Mid-Sized and Established Players; the Majority of Stakeholders are Presently based in North America and Europe
14.4. The Heightened Pace of Research in this Field is Evident from the Multiple R&D Agreements and the Rise in Number of Scientific Articles Published in the Recent Years
14.5. Development Efforts have Garnered the Attention of Various Private and Public Investors, Resulting in Significant Capital Investments, which are Likely to Provide the Necessary Boost to the Market’s Future Growth
14.6. Given the Impending Approval of Multiple Late Stage Molecules, the Market is Poised to Grow at a Significant Pace in the Coming Years
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Company A
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Chief Scientist, and Business Development Manager
15.3. Company B
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Founder and Chief Executive Officer
15.4. Company C
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Chief Executive Officer
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Stem Cell Therapies: Process of Therapy Development and Administration
Figure 3.2 Classification of Stem Cell Therapies by Type of Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Figure 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Figure 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Figure 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Figure 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Figure 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Figure 4.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Figure 4.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Figure 4.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Figure 4.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 4.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Grid Analysis
Figure 4.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Figure 4.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Figure 4.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Figure 4.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Figure 4.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Location of Stem Cell Therapy Manufacturing Facilities of Developer
Figure 4.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Mapping Regional Activity
Figure 4.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Logo Landscape
Figure 4.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2 Unmet Needs in Cardiovascular Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.3 Unmet Needs in Metabolic Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Figure 5.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Figure 5.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Figure 5.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Figure 5.8 Unmet Needs in Stem Cell Therapies for Cardiovascular Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.9 Unmet Needs in Stem Cell Therapies for Metabolic Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.10 Key Unmet Needs in Cardiovascular Disorders
Figure 5.11 Key Unmet Needs in Metabolic Disorders
Figure 6.1 Heart Failure: Types
Figure 6.2 Heart Failure: Risk Factors
Figure 6.3 Heart Failure: Symptoms
Figure 6.4 Heart Failure: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.5 Myocardial Infarction: Risk Factors
Figure 6.6 Myocardial Infarction: Distribution by Phase of Development and Type of Stem Cells
Figure 6.7 Critical Limb Ischemia: Symptoms
Figure 6.8 Critical Limb Ischemia: Risk Factors
Figure 6.9 Critical Limb Ischemia: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.10 Diabetes: Risk Factors
Figure 6.11 Diabetes: Currently Available Non-Insulin Therapies
Figure 6.12 Diabetes: Distribution by Phase of Development and Type of Stem Cells
Figure 7.1 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Cardiovascular Disorders
Figure 7.2 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Metabolic Disorders
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Figure 8.5 Partnerships and Collaborations : Activity of Big Pharmaceutical Companies
Figure 8.6 Partnerships and Collaborations: Regional Distribution
Figure 8.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 8.8 Partnerships and Collaborations: Most Active Players
Figure 9.1 Funding and Investments: Distribution by Year of Establishment and Type of Funding, 2012-2018
Figure 9.2 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Figure 9.3 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Figure 9.4 Funding and Investments: Distribution by Type of Funding
Figure 9.5 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 9.6 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Figure 9.7 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Figure 9.8 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Figure 9.9 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Figure 9.10 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Figure 9.11 Funding and Investments: Most Active Players
Figure 9.12 Funding and Investments Summary
Figure 10.1 Publications: Cumulative Trend by Year, 2013-2018
Figure 10.2 Publications: Most Popular Journals
Figure 10.3 Publications: Distribution by Type of Study
Figure 10.4 Publications: Distribution by Type of Disorder
Figure 10.5 Publications: Distribution by Type of Cardiovascular Disorders
Figure 10.6 Publications: Distribution by Type of Metabolic Disorders
Figure 10.7 Publications: Distribution by Stem Cell Lineage
Figure 10.8 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Figure 10.9 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Figure 10.10 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Figure 10.11 Publications: Emerging Areas
Figure 11.1 Stempeucel: History of Development
Figure 11.2 Stempeucel: Development / Manufacturing Process
Figure 11.3 aBMC by Cesca Therapeutics: History of Development
Figure 11.4 aBMC by Cesca Therapeutics: Development / Manufacturing Process
Figure 11.5 BCDA-01: History of Development
Figure 11.6 BCDA-01: Development / Manufacturing Process
Figure 11.7 BCDA-02: History of Development
Figure 11.8 CLBS14-NORDA: History of Development
Figure 11.9 CLBS14-NORDA: Development / Manufacturing Process
Figure 11.10 MPC-150-IM: History of Development
Figure 11.11 MPC-150-IM: Development / Manufacturing Process
Figure 11.12 PLX-PAD: Mechanism of Action
Figure 11.13 PLX-PAD: History of Development
Figure 11.14 PLX-PAD: Development / Manufacturing Process
Figure 12.1 Strimvelis: History of Development
Figure 12.2 Strimvelis: Development / Manufacturing Process
Figure 12.3 Unnamed Stem Cell Therapy by Global Cell Med: Development / Manufacturing Process
Figure 12.4 Stem Cell Educator System: History of Development
Figure 12.5 Stem Cell Educator System: Development / Manufacturing Process
Figure 13.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Till 2030 (USD Million)
Figure 13.2 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Till 2030 (USD Million)
Figure 13.3 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Till 2030 (USD Million)
Figure 13.4 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Till 2030 (USD Million)
Figure 13.5 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Till 2030 (USD Million)
Figure 13.6 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Till 2030 (USD Million)
Figure 13.7 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Till 2030 (USD Million)
Figure 13.8 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Till 2030 (USD Million)
Figure 13.9 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Till 2030 (USD Million)
Figure 13.10 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Till 2030 (USD Million)
Figure 13.11 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Till 2030 (USD Million)
Figure 13.12 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Till 2030 (USD Million)
Figure 13.13 Cellgram®-AMI: Target Patient Population
Figure 13.14 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.15 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.16 Cardiocell®: Target Patient Population
Figure 13.17 Cardiocell®: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.18 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.19 HeartSheet®: Target Patient Population
Figure 13.20 HeartSheet®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.21 HeartSheet®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.22 MPC-150-IM (Rexlemestrocel-L): Target Patient Population
Figure 13.23 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.24 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.25 BCDA-01: Target Patient Population
Figure 13.26 BCDA-01: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.27 BCDA-01: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.28 Cardiocell®: Target Patient Population
Figure 13.29 Cardiocell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.30 Cardiocell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.31 Stempeucel®: Target Patient Population
Figure 13.32 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.33 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.34 PLX-PAD: Target Patient Population
Figure 13.35 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.36 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.37 Cardiocell®: Target Patient Population
Figure 13.38 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.39 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.40 CLBS14-NORDA: Target Patient Population
Figure 13.41 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.42 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.43 BCDA-02: Target Patient Population
Figure 13.44 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.45 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.46 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Till 2030 (USD Million)
Figure 13.47 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Till 2030 (USD Million)
Figure 13.48 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Till 2030 (USD Million)
Figure 13.49 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Till 2030 (USD Million)
Figure 13.50 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Till 2030 (USD Million)
Figure 13.51 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Till 2030 (USD Million)
Figure 13.52 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Till 2030 (USD Million)
Figure 13.53 Strimvelis®: Target Patient Population
Figure 13.54 Strimvelis®: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.55 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Till 2030 (USD Million)
Figure 13.56 OTL-200: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.57 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.58 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.59 Unnamed Stem Cell Therapy by Global Cell Med: Target Patient Population
Figure 13.60 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Till 2030 (USD Million)
Figure 13.61 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Till 2030 (USD Million)
Table 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
Table 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Overview
Table 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Dose of Stem Cell Therapies
Table 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Designations Awarded to Stem Cell Therapies
Table 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Other Indications Under Evaluation
Table 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Pipeline Overview (Academic Players)
Table 4.7 Stem Cell Therapies for Stroke
Table 5.1 Unmet Needs in Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Sources / Blog Portals
Table 6.1 Heart Failure: List of Marketed Drugs
Table 6.2 Heart Failure: List of Stem Cell Therapies
Table 6.3 Myocardial Infarction: List of Marketed Drugs
Table 6.4 Myocardial Infarction: List of Stem Cell Therapies
Table 6.5 Peripheral Arterial Diseases: List of Marketed Drugs
Table 6.6 Critical Limb Ischemia: List of Stem Cell Therapies
Table 6.7 Diabetes: Current Treatment Landscape
Table 6.8 Diabetes: List of Stem Cell Therapies
Table 8.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Partnerships and Collaborations, 2012-2018
Table 9.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investments, 2012-2018
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Stem Cell Therapy for Cardiovascular and Metabolic Disorders: List of Publications, 2013-2018
Table 11.1 Stempeucel: List / Details of Clinical Trials
Table 11.2 aBMC by Cesca Therapeutics: Clinical Trials
Table 11.3 BCDA-01: List / Details of Clinical Trials
Table 11.4 BCDA-02: List / Details of Clinical Trials
Table 11.5 CLBS14-NORDA: List / Details of Clinical Trials
Table 11.6 MPC-150-IM: List / Details of Clinical Trials
Table 11.7 PLX-PAD: List / Details of Clinical Trials
Table 12.1 Strimvelis: List / Details of Clinical Trials
Table 12.2 OTL-200: List / Details of Clinical Trials
Table 12.3 Stem Cell Therapy by Global Cell Med: Clinical Trials
Table 12.4 LMSCs: List / Details of Clinical Trials
Table 12.5 Stem Cell Educator Therapy: List / Details of Clinical Trials
Table 13.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Forecasted Therapies
Table 15.1 Kadimastem: Key Highlights
Table 15.2 Seraxis: Key Highlights
Table 15.3 Xcelthera: Key Highlights
Table 16.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Table 16.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Table 16.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Table 16.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Table 16.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Table 16.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Table 16.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Table 16.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Table 16.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Table 16.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Table 16.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Table 16.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Table 16.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Table 16.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Location of Stem Cell Therapy Manufacturing Facilities of Developer
Table 16.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Table 16.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Table 16.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Table 16.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Table 16.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Table 16.20 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Table 16.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.22 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Table 16.23 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Table 16.24 Partnerships and Collaborations: Regional Distribution
Table 16.25 Partnerships and Collaborations: Most Active Players
Table 16.26 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Table 16.27 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Table 16.28 Funding and Investments: Distribution by Type of Funding
Table 16.29 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 16.30 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Table 16.31 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Table 16.32 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Table 16.33 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Table 16.34 Funding and Investments: Most Active Players
Table 16.35 Publications: Cumulative Trend by Year, 2013-2018
Table 16.36 Publications: Most Popular Journals
Table 16.37 Publications: Distribution by Type of Study
Table 16.38 Publications: Distribution by Type of Disorder
Table 16.39 Publications: Distribution by Type of Cardiovascular Disorders
Table 16.40 Publications: Distribution by Type of Metabolic Disorders
Table 16.41 Publications: Distribution by Stem Cell Lineage
Table 16.42 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Table 16.43 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Table 16.44 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Table 16.45 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Conservative Scenario, Till 2030 (USD Million)
Table 16.46 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Base Scenario, Till 2030 (USD Million)
Table 16.47 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Optimistic Scenario, Till 2030 (USD Million)
Table 16.48 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Conservative Scenario, Till 2030 (USD Million)
Table 16.49 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Base Scenario, Till 2030 (USD Million)
Table 16.50 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Optimistic Scenario, Till 2030 (USD Million)
Table 16.51 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.52 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.53 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.54 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.55 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.56 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.57 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Conservative Scenario, Till 2030 (USD Million)
Table 16.58 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Base Scenario, Till 2030 (USD Million)
Table 16.59 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Optimistic Scenario, Till 2030 (USD Million)
Table 16.60 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Conservative Scenario, Till 2030 (USD Million)
Table 16.61 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Base Scenario, Till 2030 (USD Million)
Table 16.62 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Optimistic Scenario, Till 2030 (USD Million)
Table 16.63 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Conservative Scenario, Till 2030 (USD Million)
Table 16.64 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Base Scenario, Till 2030 (USD Million)
Table 16.65 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Optimistic Scenario, Till 2030 (USD Million)
Table 16.66 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.67 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.68 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.69 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Conservative Scenario, Till 2030 (USD Million)
Table 16.70 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Base Scenario, Till 2030 (USD Million)
Table 16.71 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Optimistic Scenario, Till 2030 (USD Million)
Table 16.72 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.73 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.74 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.75 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, Till 2030 (USD Million)
Table 16.76 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Base Scenario, Till 2030 (USD Million)
Table 16.77 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Optimistic Scenario, Till 2030 (USD Million)
Table 16.78 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Conservative Scenario, Till 2030 (USD Million)
Table 16.79 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Base Scenario, Till 2030 (USD Million)
Table 16.80 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Optimistic Scenario, Till 2030 (USD Million)
Table 16.81 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.82 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.83 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Optimistic Scenario, Till 2030 (USD Million)
Table 16.84 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.85 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.86 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Optimistic Scenario, Till 2030 (USD Million)
Table 16.87 Cardiocell®: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.88 Cardiocell®: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.89 Cardiocell®: Sales Forecast for Myocardial Infarction, Optimistic Scenario, Till 2030 (USD Million)
Table 16.90 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.91 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.92 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Optimistic Scenario, Till 2030 (USD Million)
Table 16.93 HeartSheet®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.94 HeartSheet®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.95 HeartSheet®: Sales Forecast for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.96 HeartSheet®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.97 HeartSheet®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.98 HeartSheet®: Sales Forecast by Geography for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.99 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.100 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.101 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.102 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.103 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.104 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.105 BCDA-01: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.106 BCDA-01: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.107 BCDA-01: Sales Forecast for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.108 BCDA-01: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.109 BCDA-01: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.110 BCDA-01: Sales Forecast by Geography for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.111 Cardiocell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.112 Cardiocell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.113 Cardiocell®: Sales Forecast for Heart Failure, Optimistic Scenario, Till 2030 (USD Million)
Table 16.114 Cardiocell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario Till 2030 (USD Million)
Table 16.115 Cardiocell®: Sales Forecast by Geography for Heart Failure, Base Scenario Till 2030 (USD Million)
Table 16.116 Cardiocell®: Sales Forecast by Geography for Heart Failure, Optimistic Scenario Till 2030 (USD Million)
Table 16.117 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.118 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.119 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.120 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.121 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.122 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.123 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.124 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.125 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.126 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.127 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.128 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.129 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.130 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.131 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.132 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.133 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.134 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Optimistic Scenario, Till 2030 (USD Million)
Table 16.135 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.136 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.137 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.138 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.139 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.140 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.141 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.142 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.143 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.144 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.145 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.146 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.147 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.148 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.149 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.150 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.151 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.152 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Optimistic Scenario, Till 2030 (USD Million)
Table 16.153 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Conservative Scenario, Till 2030 (USD Million)
Table 16.154 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Base Scenario, Till 2030 (USD Million)
Table 16.155 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Optimistic Scenario, Till 2030 (USD Million)
Table 16.156 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, Till 2030 (USD Million)
Table 16.157 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, Till 2030 (USD Million)
Table 16.158 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Optimistic Scenario, Till 2030 (USD Million)
Table 16.159 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.160 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.161 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.162 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Conservative Scenario, Till 2030 (USD Million)
Table 16.163 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Base Scenario, Till 2030 (USD Million)
Table 16.164 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Optimistic Scenario, Till 2030 (USD Million)
Table 16.165 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, Till 2030 (USD Million)
Table 16.166 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, Till 2030 (USD Million)
Table 16.167 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Optimistic Scenario, Till 2030 (USD Million)
Table 16.168 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, Till 2030 (USD Million)
Table 16.169 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Base Scenario, Till 2030 (USD Million)
Table 16.170 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Optimistic Scenario, Till 2030 (USD Million)
Table 16.171 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Conservative Scenario, Till 2030 (USD Million)
Table 16.172 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Base Scenario, Till 2030 (USD Million)
Table 16.173 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Optimistic Scenario, Till 2030 (USD Million)
Table 16.174 Strimvelis®: Sales Forecast for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.175 Strimvelis®: Sales Forecast for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.176 Strimvelis®: Sales Forecast for ADA-SCID, Optimistic Scenario, Till 2030 (USD Million)
Table 16.177 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.178 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.179 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Optimistic Scenario, Till 2030 (USD Million)
Table 16.180 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.181 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.182 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Optimistic Scenario, Till 2030 (USD Million)
Table 16.183 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.184 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.185 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Optimistic Scenario, Till 2030 (USD Million)
Table 16.186 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.187 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.188 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Optimistic Scenario, Till 2030 (USD Million)
Table 16.189 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.190 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.191 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Optimistic Scenario, Till 2030 (USD Million)